Astrazeneca (AZN) Receivables (2016 - 2025)

Astrazeneca has reported Receivables over the past 11 years, most recently at $16.5 billion for Q4 2025.

For Q4 2025, Receivables rose 13.42% year-over-year to $16.5 billion; the TTM value through Dec 2025 reached $16.5 billion, up 13.42%, while the annual FY2025 figure was $17.2 billion, 18.16% up from the prior year.
Receivables for Q4 2025 was $16.5 billion at Astrazeneca, up from $14.6 billion in the prior quarter.
Over five years, Receivables peaked at $16.5 billion in Q4 2025 and troughed at -$1.0 billion in Q1 2021.
A 5-year average of $10.1 billion and a median of $10.7 billion in 2021 define the central range for Receivables.
Biggest five-year swings in Receivables: skyrocketed 51.2% in 2021 and later fell 22.54% in 2022.
Year by year, Receivables stood at $11.5 billion in 2021, then fell by 22.54% to $8.9 billion in 2022, then increased by 13.25% to $10.0 billion in 2023, then skyrocketed by 44.84% to $14.6 billion in 2024, then grew by 13.42% to $16.5 billion in 2025.
Business Quant data shows Receivables for AZN at $16.5 billion in Q4 2025, $14.6 billion in Q4 2024, and $10.0 billion in Q4 2023.

Peer Comparison